These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 25247339)

  • 1. A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321.
    Zhao Y; Foster NR; Meyers JP; Thomas SP; Northfelt DW; Rowland KM; Mattar BI; Johnson DB; Molina JR; Mandrekar SJ; Schild SE; Bearden JD; Aubry MC; Adjei AA
    J Thorac Oncol; 2015 Jan; 10(1):172-80. PubMed ID: 25247339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.
    Langer CJ; Movsas B; Hudes R; Schol J; Keenan E; Kilpatrick D; Yeung C; Curran W
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-89-S12-95. PubMed ID: 9331129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [
    Vera P; Thureau S; Le Tinier F; Chaumet-Riffaud P; Hapdey S; Kolesnikov-Gauthier H; Martin E; Berriolo-Riedinger A; Pourel N; Broglia JM; Boissellier P; Guillemard S; Salem N; Brenot-Rossi I; Le Péchoux C; Berthold C; Giroux-Leprieur E; Moreau D; Guillerm S; Benali K; Tessonnier L; Audigier-Valette C; Lerouge D; Quak E; Massabeau C; Courbon F; Moisson P; Larrouy A; Modzelewski R; Gouel P; Ghazzar N; Langlais A; Amour E; Zalcman G; Giraud P
    Lancet Oncol; 2024 Sep; 25(9):1176-1187. PubMed ID: 39134086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified Phase I trial.
    Socinski MA; Rosenman JG; Schell MJ; Halle J; Russo S; Rivera MP; Clark J; Limentani S; Fraser R; Mitchell W; Detterbeck FC
    Cancer; 2000 Aug; 89(3):534-42. PubMed ID: 10931452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial.
    Lau D; Leigh B; Gandara D; Edelman M; Morgan R; Israel V; Lara P; Wilder R; Ryu J; Doroshow J
    J Clin Oncol; 2001 Jan; 19(2):442-7. PubMed ID: 11208837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
    Choong NW; Vokes EE; Haraf DJ; Tothy PK; Ferguson MK; Kasza K; Rudin CM; Hoffman PC; Krauss SA; Szeto L; Mauer AM
    J Thorac Oncol; 2008 Jan; 3(1):59-67. PubMed ID: 18166842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carboplatin, S-1 and concurrent thoracic radiotherapy for elderly patients with locally advanced non-small cell lung cancer: a multicenter Phase I/II study.
    Niho S; Hosomi Y; Okamoto H; Nihei K; Tanaka H; Hida T; Umemura S; Goto K; Akimoto T; Ohe Y
    Jpn J Clin Oncol; 2019 Jul; 49(7):614-619. PubMed ID: 30916304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer.
    Kawano Y; Sasaki T; Yamaguchi H; Hirano K; Horiike A; Satouchi M; Hosokawa S; Morinaga R; Komiya K; Inoue K; Fujita Y; Toyozawa R; Kimura T; Takahashi K; Nishikawa K; Kishimoto J; Nakanishi Y; Okamoto I
    Lung Cancer; 2018 Nov; 125():136-141. PubMed ID: 30429011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial.
    Socinski MA; Rosenman JG; Halle J; Schell MJ; Lin Y; Russo S; Rivera MP; Clark J; Limentani S; Fraser R; Mitchell W; Detterbeck FC
    Cancer; 2001 Sep; 92(5):1213-23. PubMed ID: 11571735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction therapy with carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal radiotherapy in the treatment of locally advanced, unresectable non-small cell lung cancer: preliminary report of a phase I trial.
    Socinski MA; Clark JA; Halle J; Steagall A; Kaluzny B; Rosenman JG
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-117-S12-122. PubMed ID: 9331135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer.
    Piperdi B; Walsh WV; Bradley K; Zhou Z; Bathini V; Hanrahan-Boshes M; Hutchinson L; Perez-Soler R
    J Thorac Oncol; 2012 Jun; 7(6):1032-40. PubMed ID: 22534815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of low-dose paclitaxel with timed thoracic radiotherapy followed by adjuvant gemcitabine and carboplatin in unresectable stage III non-small cell lung cancer.
    Zhang J; Gay HA; Russo S; Parent T; Aljumaily R; Walker PR
    Lung Cancer; 2014 Jan; 83(1):67-72. PubMed ID: 24246506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary results of a phase II study of weekly paclitaxel (PTX) and carboplatin (CBDCA) administered concurrently with thoracic radiation therapy (TRT) followed by consolidation chemotherapy with PTX/CBDCA for stage III unresectable non-small-cell lung cancer (NSCLC).
    Kaplan B; Altýnbas M; Eroglu C; Karahacioglu E; Er O; Ozkan M; Bilgin M; Canoz O; Gulmez I; Gulec M
    Am J Clin Oncol; 2004 Dec; 27(6):603-10. PubMed ID: 15577439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of concurrent twice-weekly paclitaxel and weekly cisplatin with radiation therapy for stage III non-small cell lung cancer.
    Solomon B; Ball DL; Richardson G; Smith JG; Millward M; MacManus M; Michael M; Wirth A; O'Kane C; Muceniekas L; Ryan G; Rischin D
    Lung Cancer; 2003 Sep; 41(3):353-61. PubMed ID: 12928126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial.
    Rosenman JG; Halle JS; Socinski MA; Deschesne K; Moore DT; Johnson H; Fraser R; Morris DE
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):348-56. PubMed ID: 12243807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer.
    Omori S; Harada H; Mori K; Hisamatsu Y; Tsuboguchi Y; Yoshioka H; Morinaga R; Daga H; Kurata T; Takahashi T
    Invest New Drugs; 2022 Feb; 40(1):106-114. PubMed ID: 34495421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of concurrent real-time tumor-tracking thoracic radiation therapy with paclitaxel and carboplatin in locally advanced non-small cell lung cancer.
    Sakakibara-Konishi J; Oizumi S; Kinoshita I; Shinagawa N; Kikuchi J; Kato M; Inoue T; Katoh N; Onimaru R; Shirato H; Dosaka-Akita H; Nishimura M
    Lung Cancer; 2011 Nov; 74(2):248-52. PubMed ID: 21397973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117.
    Bradley JD; Bae K; Graham MV; Byhardt R; Govindan R; Fowler J; Purdy JA; Michalski JM; Gore E; Choy H
    J Clin Oncol; 2010 May; 28(14):2475-80. PubMed ID: 20368547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study).
    Choy H; Devore RF; Hande KR; Porter LL; Rosenblatt P; Yunus F; Schlabach L; Smith C; Shyr Y; Johnson DH
    Int J Radiat Oncol Biol Phys; 2000 Jul; 47(4):931-7. PubMed ID: 10863062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.